After surprise FDA win, Aveo reverts to normal as partner splits, giving back unwanted asset

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 15, 2021 at 11:22: AM
via After getting an FDA approval for its long-suffering cancer med from the FDA this month, Aveo’s brief positive news was upset by reverting to type after partner CANbridge said thanks but no thanks to an experimental drug.

article source
 

<



Similar threads

cafead
Elevar, Hengrui eye quick refile for PD-1 liver cancer combo after surprise FDA rejection
Replies
0
Views
21
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Lilly’s Donanemab Hit with Surprise Delay, Set to Face FDA Adcomm
Replies
0
Views
142
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use
Replies
0
Views
351
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Regeneron&#039;s high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups
Replies
0
Views
267
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
In a surprise approval, FDA green-lights Incyte&#039;s PD-1 inhibitor to treat rare cancer type
Replies
0
Views
322
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote